Download PDF
Exp Clin Endocrinol Diabetes 1991; 97(2/03): 275-285
DOI: 10.1055/s-0029-1211078
Original

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Radioiodine Treatment of Basedow's Disease: Interference and Influence Factors, Risk Estimation

C. Reiners
  • Clinic for Nuclear Medicine, University of Essen (Head: Prof. Dr. C. Reiners)
Further Information

Publication History

Publication Date:
16 July 2009 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

I-131 treatment of Basedow's disease is effective and safe. Relatively high energy doses to the thyroid in the range of 150—200 Gray are needed in endemic goiter areas, where immunogenic hyperthyroidism may coincide with functional autonomy. Induction of euthyroidism by low doses of antithyroid drugs (methimazole, carbimazole) before I-131 treatment prevents complications and has no significant influence on outcome of I-131 therapy. As compared to alternative therapeutic modalities, the risks of I-131 are low.